Location New York, New York, United States Regions Greater New York Area, East Coast, Northeastern US Gender Male
LinkedIn View on LinkedIn
Alvin Luk, Senior Vice President and Chief Medical Officer at Shanghai Henlius Biotech Inc., holds an MBA from Harvard Business School, earned his doctoral degree in Neuroscience from the University of California San Francisco Medical School (UCSF) and is certified for clinical research from the Association of Clinical Research Professionals.
Previously,Dr. Luk has held executive positions at companies such as Spark, Biogen, BayerAG, Avigen (Sanofi) and Tularik (Amgen). He has over 26 years of global drug development, strategic management and clinical medical leadership experience. During 2006-2009, Dr. Luk was a member of the USA FDA Clinical Design Committee focusing on adaptive clinical trial designs to shorten drug development timeline. His early researches were focusing on gene regulation and expression, particularly emphasis on rare diseases, oncological diseases,biologics and regenerative medicines. Under his leadership in the development strategy for inherited retinal, neurodegenerative and hemophilia diseases, Dr.Luk has recently received the first US FDA AAV-gene therapy marketing approval and has won regulatory marketing approvals of 15 products as of today. Dr. Luk has published more than 50 scientific and medical articles in highly regarded peer-reviewed journals and book chapters and is an inventor on 8 patent applications.
